Arkema Shares at €62.85: Analysts Divided
The specialty chemicals company's stock takes a breather this Thursday, May 7, at €62.85 midday, after a nearly 3% rise the previous day. This movement occurs in a nearly stable CAC 40, down 0.11%. Two analyst reports released this Thursday offer opposing conclusions.
Deutsche Bank and Alphavalue Disagree on the Case
Two analyst adjustments frame ARKEMA's session this May 7. Deutsche Bank slightly raises its price target to €52 from €50, while maintaining a 'hold' rating. The gap with the current price of €62.85 implies a potential downside of about 17%. On the other hand, Alphavalue adjusts its target from €73.30 to €73.50 and reaffirms its 'accumulate' rating, indicating a potential upside of about 17% at today's price. This divergence extends a debate that has been ongoing about the stock. The German office has been cautious for several months about the group's ability to restore its margins, in a context of weakened Advanced Materials. The publication of the Q1 2026 results confirmed an EBITDA decline of 14% to 283 million euros, affected by an unfavorable currency effect of about 20 million euros. However, the group has maintained its target of slight EBITDA growth at constant exchange rates for the year. The analyst consensus remains divided on the 2026 trajectory.
RSI at 66 Indicates the Rebound is Losing Steam
In terms of indicators, today's decline is in a tense zone. The stock is trading at its resistance level of €64.20, already tested at the session's high the previous day. The RSI at 66 is approaching the overbought threshold (70) after several sessions of gains, which corresponds to the pause observed at €62.85. The Bollinger Bands place the price in the upper half, close to the upper boundary at €63.69. Beyond today's movement, Arkema maintains an 8.36% gain over three months and remains well above its 200-day moving average at €56.05. The stock is among the notable declines in the SBF 120 this Thursday, in an index that is down 0.15% during the session. The next appointment on the financial calendar is the publication of the semi-annual results, scheduled for July 30, 2026.
